AOD9604 research grew out of a structural question about human growth hormone: can the effects of a 191-residue hormone on lipid metabolism be reproduced by a short piece of its sequence? The answer reported in the 1990s was that the C-terminal region alone retained measurable activity in rodent adipose tissue, and that observation generated a research programme that ran for two decades. This article reviews the chemistry, the rodent literature, the analytical work that followed, and the practical considerations for laboratories handling AOD9604 and HGH fragment 176-191.
Growth hormone and the idea of separable domains
Human growth hormone is a four-helix bundle that signals by dimerizing the growth hormone receptor through two distinct binding sites, initiating JAK2-STAT5 signaling. That mechanism accounts for its growth-promoting and IGF-1-inducing activities.
Work in the 1980s and 1990s suggested that the hormone's effects on lipid handling might be separable from receptor dimerization, and mapped candidate activity to the C-terminal region. Wu and Ng reported in 1993 that the synthetic C-terminal peptide hGH 177-191 (Leu-Arg-Ile-Val-Gln-Cys-Arg-Val-Ser-Glu-Gly-Ser-Cys-Gly-Phe) showed antilipogenic activity comparable to the intact hormone, assessed in adipose tissue from treated rats, while no significant lipolytic effect was detected by glycerol release from epididymal fat pads in the same study [1]. They concluded that the functional domain responsible for the antilipogenic activity lies in the C-terminal region.
The distinction between antilipogenic and lipolytic is worth pausing on, because later literature often blurs it:
- Lipolysis is the hydrolysis of stored triacylglycerol, classically measured as glycerol or non-esterified fatty acid release.
- Lipogenesis is the synthesis of fatty acids and triacylglycerol, measured by labelled-precursor incorporation or by lipogenic enzyme activity.
The 1993 report describes an effect on the second, not the first [1].
AOD9604 as a defined analog
AOD9604 is the designation given to a synthetic analog of this C-terminal domain, developed with an added N-terminal tyrosine residue. The series also included the related analog AOD9401, characterized in Zucker fatty rats in a 2000 study that examined molecular and cellular actions on lipid metabolism [2].
Two chemical features shape laboratory handling:
| Feature | Implication |
|---|---|
| Two cysteine residues | Capable of forming an intramolecular disulfide; oxidation state affects mass and conformation |
| Added N-terminal tyrosine | Provides a UV chromophore at 280 nm useful for quantification |
| Short, moderately hydrophobic sequence | Reversed-phase HPLC behaves predictably; solubility in neutral aqueous buffer is acceptable |
Disulfide state is the item most often overlooked. A reduced and an oxidized form differ by 2 Da, which a good LC-MS method resolves. Our article on mass spectrometry and peptide identity confirmation explains how to read those spectra, and lot-specific analytical data for our catalog is posted on the lab reports page.
What the rodent studies reported
The rodent literature is concentrated in a handful of papers from the late 1990s and early 2000s.
Oral administration study (2000). Heffernan and colleagues examined a synthetic fragment of human growth hormone given orally to mice, reporting effects on lipid metabolism parameters in that model [3]. The study is cited mainly for its route-of-delivery findings in the animal model rather than for mechanism.
Metabolic characterization (2000). Ng and colleagues published metabolic studies of the synthetic lipolytic domain AOD9604, describing its behaviour in rodent systems and comparing it with the parent hormone [4].
Chronic exposure in obese and knockout mice (2001). The most mechanistically informative study compared chronic exposure to human growth hormone and to AOD9604 in obese mice and in β3-adrenergic receptor knockout mice [5]. The β3-AR knockout arm was included because β3-adrenergic signaling is the canonical lipolytic pathway in rodent adipose tissue; if the fragment's effects persisted without β3-AR, they could not be explained by that route. The study reported changes in lipid metabolism measures in the treated mouse groups and examined the contribution of β3-AR expression [5].
Fat oxidation in obese mice (2001). A companion paper reported increased fat oxidation and reduced body weight in obese mice after chronic exposure to human growth hormone or to a modified C-terminal fragment [6].
All of the above are observations in mouse or rat models. Species differences in adipose tissue adrenergic receptor complement are substantial, and rodent β3-AR biology does not map directly onto other species, which is one reason the mechanism has remained contested.
A different experimental context
AOD9604 has also been examined outside lipid metabolism. A 2015 study reported on intra-articular injection of AOD9604 with or without hyaluronic acid in a collagenase-induced knee osteoarthritis model in rabbits [7]. That work is unrelated to the adipose literature and illustrates how a compound can be repurposed into an entirely separate model system.
Analytical and provenance considerations
Because AOD9604 has appeared in sports-drug-testing literature, there is an unusually good analytical record for a compound of this size.
- Cox and colleagues published on the detection and in vitro metabolism of AOD9604, characterizing the fragments generated and the methods used to identify them [8]. For a laboratory, this is a useful reference when designing stability or plasma-incubation studies, since it indicates which cleavage products to expect.
- Because the peptide overlaps with a human hormone sequence, immunoassays raised against growth hormone may or may not cross-react. Any quantification strategy should state whether the antibody epitope lies within the fragment.
Provenance matters here as much as chemistry. Sequence-similar fragments, differing by one or two residues or by an N-terminal addition, are easy to confuse on a label but distinguishable by exact mass. Recording and cross-checking lot identifiers is the practical safeguard, a point we cover in lot numbers and traceability in peptide research.
Designing experiments in this area
A reasonable in vitro design uses differentiated 3T3-L1 adipocytes or primary adipocytes and measures the two processes separately:
- Lipogenesis: incorporation of ¹⁴C-acetate or ²H-labelled water into triacylglycerol; lipogenic enzyme activity (ACC, FAS).
- Lipolysis: glycerol and non-esterified fatty acid release into medium, with a β-adrenergic agonist as a positive control.
- Receptor attribution: compare growth hormone receptor-expressing and -deficient cells; measure STAT5 phosphorylation to test whether the canonical pathway is engaged at all.
- Peptide integrity: sample medium at the end of the incubation and confirm by LC-MS that intact peptide remains, since short peptides can be degraded during long incubations.
Reporting the disulfide state, the peptide concentration verified by amino acid analysis or A280, and the incubation duration alongside results makes cross-lab comparison possible, which this literature has historically lacked.
Key takeaways
- The C-terminal region of human growth hormone was reported in 1993 to reproduce the hormone's antilipogenic activity in rat adipose tissue, without a detected lipolytic effect in that assay [1].
- AOD9604 is a synthetic analog of that domain carrying an added N-terminal tyrosine; AOD9401 is a related analog studied in Zucker fatty rats [2].
- Rodent studies examined oral delivery, chronic exposure in obese mice, and β3-adrenergic receptor knockout mice to probe the pathway [3, 4, 5, 6].
- A separate rabbit study examined intra-articular AOD9604 in an osteoarthritis model [7].
- Disulfide state, exact mass confirmation and lot traceability are the practical laboratory controls [8].
This article summarizes published research for informational purposes. All Ascent Sciences products are for laboratory research use only and are not for human or animal consumption.
References
- Wu Z, Ng FM. Antilipogenic action of synthetic C-terminal sequence 177-191 of human growth hormone. Biochemistry and Molecular Biology International. 1993;30(1):187-196. PubMed
- Ng FM, Jiang WJ, Gianello R, et al. Molecular and cellular actions of a structural domain of human growth hormone (AOD9401) on lipid metabolism in Zucker fatty rats. Journal of Molecular Endocrinology. 2000;25(3):287-298. PubMed
- Heffernan MA, Jiang WJ, Thorburn AW, Ng FM. Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism. American Journal of Physiology Endocrinology and Metabolism. 2000;279(3):E501-E507. PubMed
- Ng FM, Sun J, Sharma L, et al. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Hormone Research. 2000;53(6):274-278. PubMed
- Heffernan M, Summers RJ, Thorburn A, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001;142(12):5182-5189. PubMed
- Heffernan MA, Thorburn AW, Fam B, et al. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. International Journal of Obesity and Related Metabolic Disorders. 2001;25(10):1442-1449. PubMed
- Kwon DR, Park GY. Effect of intra-articular injection of AOD9604 with or without hyaluronic acid in rabbit osteoarthritis model. Annals of Clinical and Laboratory Science. 2015;45(4):426-432. PubMed
- Cox HD, Smeal SJ, Hughes CM, et al. Detection and in vitro metabolism of AOD9604. Drug Testing and Analysis. 2015;7(1):31-38. PubMed
Frequently asked questions
How do AOD9604 and HGH fragment 176-191 differ?
Both derive from the C-terminal region of human growth hormone. The fragment corresponds to residues of that region, while AOD9604 is a modified version of the C-terminal sequence carrying an added N-terminal tyrosine; published papers describe it as a synthetic analog of the hGH 177-191 domain.
What was the original observation?
A 1993 study reported that the synthetic C-terminal sequence 177-191 of human growth hormone reproduced the antilipogenic activity of the intact hormone in rat adipose tissue preparations, without a significant lipolytic effect in that assay.
Why were beta3-adrenergic receptor knockout mice used?
To test whether the fragment's activity in mice required beta3-adrenergic signaling. A 2001 Endocrinology study compared obese mice and beta3-AR knockout mice after chronic exposure.
Does the fragment act through the growth hormone receptor?
The published rationale is that the C-terminal domain separates lipid-related activity from the growth-promoting, receptor-dimerizing activity of the full hormone. A distinct receptor for the fragment has not been established in the literature.
All Ascent Sciences products are for laboratory research use only and are not for human or animal consumption. This article summarizes published research and is not medical advice. See our Research Use Agreement.